Method for screening peptides for use in immunotherapy

US7976843B2 · kind B2 · utility

Assignees

• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• INSTITUT GUSTAVE ROUSSY · FR

Inventors

• Kostas Kosmatopoulos · Paris, FR
• Sophie Tourdot · Paris, FR
• Antonio Scardino · Paris, FR
• David Gross · Mevaseret Tsiyon, IL

Key dates

• Filing date: Aug 6, 2008
• Grant date: Jul 12, 2011
• Expiry date: Aug 16, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16222
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).